Correction added on November 25, 2019 after first online publication: the copyright line has been revised.

In a recently published article in the *Annals of Neurology*, Bakshi and colleagues determined the concentration of the antioxidant urate in serum samples from \~1,500 individuals with or without *LRRK2* mutations that were affected or unaffected by Parkinson disease (PD).[1](#ana25510-bib-0001){ref-type="ref"} In 3 independent cohorts, they detected significantly lower levels of urate in manifesting (LRRK2^+^/PD^+^) compared to nonmanifesting (LRRK2^+^/PD^−^) *LRRK2* mutation carriers and speculated that the elevated PD risk in the LRRK2^+^/PD^+^ group may be due to increased LRRK2 activity,[2](#ana25510-bib-0002){ref-type="ref"} which can interfere with urate‐sensitive pathways including Nrf2 antioxidant signaling.[1](#ana25510-bib-0001){ref-type="ref"} There is evidence that Nrf2 counteracts mitochondrial damage by triggering the expression of mitochondrial transcription factor A (TFAM).[3](#ana25510-bib-0003){ref-type="ref"} TFAM functions as a mitochondrial transcription factor, but the protein is equally involved in mitochondrial DNA (mtDNA) replication and packaging of the mitochondrial genome into nucleoids.[4](#ana25510-bib-0004){ref-type="ref"}

In search of a penetrance biomarker for LRRK2‐associated PD, we explored the link between mtDNA integrity and disease progression. Employing a high‐throughput multiplex real‐time polymerase chain reaction assay,[4](#ana25510-bib-0004){ref-type="ref"} we assessed the levels of mitochondrial major arc deletions in fibroblasts from manifesting (LRRK2^+^/PD^+^; n = 10, mean age ± standard deviation \[SD\] = 66.0 ± 12.5 years) and nonmanifesting carriers (LRRK2^+^/PD^−^; n = 21, mean age ± SD = 58.5 ± 15.4 years) of the G2019S mutation and healthy mutation‐negative controls (n = 10, mean age ± SD = 58.3 ± 14.5 years). mtDNA deletion levels were derived from the *MT‐ND4*:*MT‐ND1* ratio. Analysis of variance (ANOVA) testing, regression models, and investigation of sensitivity with receiver operating characteristic (ROC) curves were constructed using statistical analysis software (JMP 14; SAS Institute, Cary, NC). The mean values for *MT‐ND4*:*MT‐ND1* differed significantly between the 3 groups (1‐way ANOVA: *F* = 13.26, *p* \< 0.0001), with the highest deletion levels in manifesting G2019S mutation carriers (significance levels after Bonferroni correction for multiple testing: controls vs LRRK2^+^/PD^−^, *p* = 0.0047; controls vs LRRK2^+^/PD^+^, *p* \< 0.0001; LRRK2^+^/PD^−^ vs LRRK2^+^/PD^+^, *p* = 0.0355). The levels of somatic mtDNA deletions in *LRRK2* mutation carriers were associated with PD status even after adjusting for age in a logistic regression model, where the disease status is the dependent variable and the covariates are the *MT‐ND4*:*MT‐ND1* ratio and age (LRRK2^+^/PD^+^ vs LRRK2^+^/PD^−^, odds ratio = 2.40, 95% confidence interval = 1.05--5.16, *p* = 0.014). The sensitivity of the *MT‐ND4*:*MT‐ND1* ratio as a biological marker was assessed using covariant‐adjusted ROC analysis. The resulting areas under the curves (\>0.75) indicated good discrimination for all investigated comparisons: (1) controls versus all individuals with LRRK2 G2019S, (2) LRRK2^+^/PD^+^ versus all unaffected individuals, and (3) LRRK2^+^/PD^+^ versus LRRK2^+^/PD^−^ (Fig).

![Analysis of mtDNA major arc deletions in controls, and nonmanifesting (LRRK2^+^/PD^−^) and manifesting carriers (LRRK2^+^/PD^+^) of the LRRK2 G2019S mutation. (A) *MT‐ND4*:*MT‐ND1* ratios differed significantly between the control, LRRK2^+^/PD^−^, and LRRK2^+^/PD^+^ groups, as determined by 1‐way analysis of variance (*p* \< 0.0001). Dots indicate mean values per person derived from 3 independent experiments. In addition, group mean values with standard deviations and 95% confidence intervals (CIs) are shown. A logistic regression model was used to predict the outcome of Parkinson disease (PD) status in *LRRK2* mutation carriers with *MT‐ND4*:*MT‐ND1* ratios, adjusted by age (LRRK2^+^/PD^−^ vs LRRK2^+^/PD^+^, odds ratio = 2.40, 95% CI = 1.05--5.16, *p* = 0.014). (B--D) Receiver operating characteristic curves. Areas under the curve (AUCs) and 95% CI are given for different group comparisons as indicated in the tables.](ANA-86-324-g001){#ana25510-fig-0001}

Increased levels of reactive oxygen species resulting from reduced urate concentrations in manifesting G2019S mutation carriers may also be the cause of the mtDNA phenotype[5](#ana25510-bib-0005){ref-type="ref"} observed in this study. Our finding of increased mtDNA deletions in LRRK2^+^/PD^+^ compared to LRRK2^+^/PD^−^ individuals supports a link between LRRK2 kinase activity,[2](#ana25510-bib-0002){ref-type="ref"} urate‐mediated Nrf2 signaling, and oxidative stress in the progression of LRRK2‐associated PD.
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